Physicians' Academy for Cardiovascular Education

Residual risk and HDL:

Slides (presentation) - June 1, 2011

Residual risk and HDL: New perspectives from recent clinical trials


Prof. Chris Packard, MD
Western Infirmary,
Glasgow, United Kingdom

MC Lipid Innovations - Prague -  May 2011




Click on slides to view presentation


HDL and endotoxemia
HDL and atherosclerosis
SATURN
CETP as a therapeutic target
CETP in HDL physiology
CETP in HDL physiology
CETP Genetics and CHD risk
CETP genetics and CHD risk
Epidemiology of CETP
CETP mass and CHD incidence in PROVE-IT
The Inhibition of Cholesteryl Ester Transfer Protein
Pharmacodynamics of CETP regulation
Clinical trials of HDL increase by CETP inhibition
Efficacy of anacetrapib in DEFINE
Safety of anacetrapib in DEFINE
Effects of CETP regulation on plasma lipids
Differential regulation of CETP
dal-OUTCOMES Study design
Testing the HDL paradigm
Summary

Share this page with your colleagues and friends: